Learning from COVID-19 Vaccines

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Epidemiology & Public Health".

Deadline for manuscript submissions: closed (20 August 2023) | Viewed by 3416

Special Issue Editor


E-Mail Website
Guest Editor
Institute for Interdisciplinary Innovation in healthcare, Université libre de Bruxelles, 1180 Brussels, Belgium
Interests: immunology; healthcare innovation; public health

Special Issue Information

Dear Colleagues,

The extraordinarily successful development of COVID-19 vaccines will be a landmark in the history of vaccinology. Firstly, it opens new avenues to fight existing and future infectious threats. Secondly, it leads to the reconsideration of vaccines as efficient weapons against cancer and chronic disorders. Thirdly, it is changing the economic and political visions of global health. The landscape of vaccinology will undoubtedly dramatically evolve in the coming years, with major impacts on clinical medicine. The advances will be increasingly dependent on interdisciplinary approaches, involving not only immunology, but also genetics, chemistry, microbiology, regulatory science and artificial intelligence.

For this series, we encourage submissions that highlight the future of vaccinology based on innovative approaches. Although this list is non-limitative, we will welcome papers on the following themes:

  • Correlates of protection induced by vaccines;
  • Vaccine hesitancy;
  • Vaccine safety;
  • Universal vaccines against microbial variants;
  • Cancer vaccines;
  • Vaccines against chronic disorders;
  • Genetic determinants of vaccine responses;
  • Passive immunotherapy for infectious diseases;
  • Artificial intelligence for vaccine development and vaccine monitoring.

Prof. Dr. Michel Goldman
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • COVID-19 vaccines
  • vaccinology
  • clinical medicine
  • vaccine safety
  • cancer vaccines

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 1140 KiB  
Article
Evidence of Validity and Measurement Invariance by Gender of the Vaccination Attitudes Examination (VAX) Scale in Colombian University Students
by Begoña Espejo, Marta Martín-Carbonell, Kelly Carolina Romero-Acosta, Martha Fernández-Daza and Yadid Paternina
J. Clin. Med. 2022, 11(16), 4682; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm11164682 - 10 Aug 2022
Cited by 4 | Viewed by 1460
Abstract
Background: Having a valid tool to assess attitudes toward vaccination and identify the concerns that drive vaccine refusal can facilitate population studies and help guide public health interventions. The objective of this study has been to adapt the Vaccination Attitudes Examination (VAX) scale [...] Read more.
Background: Having a valid tool to assess attitudes toward vaccination and identify the concerns that drive vaccine refusal can facilitate population studies and help guide public health interventions. The objective of this study has been to adapt the Vaccination Attitudes Examination (VAX) scale in Colombian university students and to study its psychometric properties in a non-probabilistic sample of 1074 Colombian university students. Methods: A confirmatory factor analysis was used to study the factorial structure. A structural equation model was tested to study concurrent validity and to check whether the factors predicted having received the coronavirus vaccine. Gender-based measurement invariance was also studied for the best model. Results: The results support the structure of four related factors. The composite reliability index was good for all the factors, but the average variance extracted was not as good for the second factor. There was strong measurement invariance by gender, and two factors are good predictors of being vaccinated or not. Conclusions: The VAX has shown construct and concurrent validity and is a reliable tool for evaluating attitudes towards vaccines in university students in Colombia. It may help guide the implementation of actions for the National Vaccination Plan and institutional policies. Full article
(This article belongs to the Special Issue Learning from COVID-19 Vaccines)
Show Figures

Figure 1

22 pages, 320 KiB  
Article
COVID-19 Vaccination Status, Attitudes, and Values among US Adults in September 2021
by Matthew Z. Dudley, Benjamin Schwartz, Janesse Brewer, Lilly Kan, Roger Bernier, Jennifer E. Gerber, Haley Budigan Ni, Tina M. Proveaux, Rajiv N. Rimal and Daniel A. Salmon
J. Clin. Med. 2022, 11(13), 3734; https://0-doi-org.brum.beds.ac.uk/10.3390/jcm11133734 - 28 Jun 2022
Cited by 10 | Viewed by 1395
Abstract
Background: The Delta COVID-19 variant caused a resurgence in cases and deaths during the summer of 2021, particularly among the unvaccinated, highlighting the need to increase vaccine coverage. We describe a survey conducted in September 2021, in the midst of the Delta variant [...] Read more.
Background: The Delta COVID-19 variant caused a resurgence in cases and deaths during the summer of 2021, particularly among the unvaccinated, highlighting the need to increase vaccine coverage. We describe a survey conducted in September 2021, in the midst of the Delta variant surge, after the FDA fully approved Pfizer-BioNTech’s vaccine for ages 16+ and issued an emergency use authorization for ages 12–15. Methods and Findings: US adults were surveyed to measure COVID-19 vaccination status, intentions, attitudes, values, and trust in public health authorities. More than three-quarters (77%) reported receiving at least one dose of COVID-19 vaccination. Of the unvaccinated, 6% intended to vaccinate, 40% were unlikely to ever vaccinate, and 55% remained uncertain. Most of the unvaccinated were <45 years old (62%), without a bachelor’s degree (83%), earning less than $85,000 annually (74%), and Republican/Independent (66%). Concerns among the unvaccinated-yet-still-uncertain included the vaccines’ safety (86%), speed of development (86%), and suspicion of government (79%) and pharmaceutical companies (69%). Most (86%) of the unvaccinated reported they would not vaccinate if mandated by their employer. About one third (34%) of the unvaccinated reported facing at least one barrier to vaccination. Conclusion: More than half of unvaccinated adults remained uncertain about COVID-19 vaccination, indicating an opportunity to support their decision making. Public health must increase easy and equitable access to vaccination and renew efforts to provide unvaccinated populations access to information from trusted sources. Full article
(This article belongs to the Special Issue Learning from COVID-19 Vaccines)
Back to TopTop